Clinical trial · no report yet · Phase 2
COCOON
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- NCT06120140 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab IV; Amivantamab SC; Lazertinib; Doxycycline; Minocycline; Clindamycin; Chlorhexidine; Noncomedogenic skin moisturizer; Ruxolitinib; Tacrolimus; Zinc gluconate; Propranolol; Timolol; Clobetasol
- Arms
- Arm A: Enhanced Dermatologic Management · Experimental
- Arm B: Standard-of-Care Dermatologic Management · Active comparator
- Sub-study: Cohort A: Ruxolitinib · Experimental
- Sub-study: Cohort B: Tacrolimus · Experimental
- Amivantamab Subcutaneous (SC) Expansion Cohort: Standard Schedule · Experimental
- Amivantamab SC Expansion Cohort: Modified Schedule · Experimental
- Enrollment
- 305
- Primary outcomes
- Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment
- Sponsor
- Janssen Research & Development, LLC
- Start
- Feb 16, 2024
- Primary completion
- May 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06120140 · updated Sep 25, 2026
Publications
linked from the registry- Cho BC, Li W, Spira AI, Sauder M, Feldman J, Bozorgmehr F, Mak M, Smith J, Voon PJ, Liu B, Tian P, Tan JL, Yang CT, Shih JY, Karadurmus N, Cundom JE, Bertollo G, Cicin I, Nieva J, Ortega-Granados AL, Tomasini P, Nguyen D, Felip E, Schuchard J, Murphy SP, Anderson BG, Romero T, Xia Y, Sheng S, Bauml JM, Mahadevia PJ, Kam J, Nematian-Samani M, Simoes J, Wildgust M, Girard N. Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. J Thorac Oncol. 2025 Oct;20(10):1517-1530. doi: 10.1016/j.jtho.2025.07.117. Epub 2025 Sep 9. PubMed 40923969